The fate of mesenchymal stem cells transplanted into immunocompetent neonatal mice: Implications for skeletal gene therapy via stem cells

Christopher Niyibizi, Sujing Wang, Zhibao Mi, Paul D. Robbins

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

To explore the feasibility of skeletal gene and cell therapies, we transduced murine bone marrow-derived mesenchymal stem cells (MSCs) with a retrovirus carrying the enhanced green fluorescent protein and zeocin-resistance genes prior to transplantation into 2-day-old immunocompetent neonatal mice. Whole-body imaging of the recipient mice at 7 days post-systemic cell injection demonstrated a wide distribution of the cells in vivo. Twenty-five days posttransplantation, most of the infused cells were present in the lung as assessed by examination of the cells cultured from the lungs of the recipient mice. The cells persisted in lung and maintained a high level of gene expression and could be recovered from the recipient mice at 150 days after cell transplantation. A significant number of GFP-positive cells were also present in the bones of the recipient mice at 35 days post-cell transplantation. Recycling of the cells recovered from femurs of the recipient mice at 25 days posttransplantation by repeated injections into different neonatal mice resulted in the isolation of a clone of cells that was detected in bone and cartilage, but not in lung and liver after systemic injection. These data demonstrate that MSCs persist in immunocompetent neonatal mice, maintain a high level of gene expression, and may participate in skeletal growth and development of the recipient animals.

Original languageEnglish (US)
Pages (from-to)955-963
Number of pages9
JournalMolecular Therapy
Volume9
Issue number6
DOIs
StatePublished - Jun 1 2004

Fingerprint

Mesenchymal Stromal Cells
Genetic Therapy
Stem Cells
Lung
Cell Transplantation
Injections
Gene Expression
Whole Body Imaging
Bone and Bones
Retroviridae
Cell- and Tissue-Based Therapy
Growth and Development
Femur
Cartilage
Cultured Cells
Clone Cells
Transplantation
Bone Marrow
Liver
Genes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

@article{4c19199340564b2eb8589a6e8570b85c,
title = "The fate of mesenchymal stem cells transplanted into immunocompetent neonatal mice: Implications for skeletal gene therapy via stem cells",
abstract = "To explore the feasibility of skeletal gene and cell therapies, we transduced murine bone marrow-derived mesenchymal stem cells (MSCs) with a retrovirus carrying the enhanced green fluorescent protein and zeocin-resistance genes prior to transplantation into 2-day-old immunocompetent neonatal mice. Whole-body imaging of the recipient mice at 7 days post-systemic cell injection demonstrated a wide distribution of the cells in vivo. Twenty-five days posttransplantation, most of the infused cells were present in the lung as assessed by examination of the cells cultured from the lungs of the recipient mice. The cells persisted in lung and maintained a high level of gene expression and could be recovered from the recipient mice at 150 days after cell transplantation. A significant number of GFP-positive cells were also present in the bones of the recipient mice at 35 days post-cell transplantation. Recycling of the cells recovered from femurs of the recipient mice at 25 days posttransplantation by repeated injections into different neonatal mice resulted in the isolation of a clone of cells that was detected in bone and cartilage, but not in lung and liver after systemic injection. These data demonstrate that MSCs persist in immunocompetent neonatal mice, maintain a high level of gene expression, and may participate in skeletal growth and development of the recipient animals.",
author = "Christopher Niyibizi and Sujing Wang and Zhibao Mi and Robbins, {Paul D.}",
year = "2004",
month = "6",
day = "1",
doi = "10.1016/j.ymthe.2004.02.022",
language = "English (US)",
volume = "9",
pages = "955--963",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

The fate of mesenchymal stem cells transplanted into immunocompetent neonatal mice : Implications for skeletal gene therapy via stem cells. / Niyibizi, Christopher; Wang, Sujing; Mi, Zhibao; Robbins, Paul D.

In: Molecular Therapy, Vol. 9, No. 6, 01.06.2004, p. 955-963.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The fate of mesenchymal stem cells transplanted into immunocompetent neonatal mice

T2 - Implications for skeletal gene therapy via stem cells

AU - Niyibizi, Christopher

AU - Wang, Sujing

AU - Mi, Zhibao

AU - Robbins, Paul D.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - To explore the feasibility of skeletal gene and cell therapies, we transduced murine bone marrow-derived mesenchymal stem cells (MSCs) with a retrovirus carrying the enhanced green fluorescent protein and zeocin-resistance genes prior to transplantation into 2-day-old immunocompetent neonatal mice. Whole-body imaging of the recipient mice at 7 days post-systemic cell injection demonstrated a wide distribution of the cells in vivo. Twenty-five days posttransplantation, most of the infused cells were present in the lung as assessed by examination of the cells cultured from the lungs of the recipient mice. The cells persisted in lung and maintained a high level of gene expression and could be recovered from the recipient mice at 150 days after cell transplantation. A significant number of GFP-positive cells were also present in the bones of the recipient mice at 35 days post-cell transplantation. Recycling of the cells recovered from femurs of the recipient mice at 25 days posttransplantation by repeated injections into different neonatal mice resulted in the isolation of a clone of cells that was detected in bone and cartilage, but not in lung and liver after systemic injection. These data demonstrate that MSCs persist in immunocompetent neonatal mice, maintain a high level of gene expression, and may participate in skeletal growth and development of the recipient animals.

AB - To explore the feasibility of skeletal gene and cell therapies, we transduced murine bone marrow-derived mesenchymal stem cells (MSCs) with a retrovirus carrying the enhanced green fluorescent protein and zeocin-resistance genes prior to transplantation into 2-day-old immunocompetent neonatal mice. Whole-body imaging of the recipient mice at 7 days post-systemic cell injection demonstrated a wide distribution of the cells in vivo. Twenty-five days posttransplantation, most of the infused cells were present in the lung as assessed by examination of the cells cultured from the lungs of the recipient mice. The cells persisted in lung and maintained a high level of gene expression and could be recovered from the recipient mice at 150 days after cell transplantation. A significant number of GFP-positive cells were also present in the bones of the recipient mice at 35 days post-cell transplantation. Recycling of the cells recovered from femurs of the recipient mice at 25 days posttransplantation by repeated injections into different neonatal mice resulted in the isolation of a clone of cells that was detected in bone and cartilage, but not in lung and liver after systemic injection. These data demonstrate that MSCs persist in immunocompetent neonatal mice, maintain a high level of gene expression, and may participate in skeletal growth and development of the recipient animals.

UR - http://www.scopus.com/inward/record.url?scp=3042775005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042775005&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2004.02.022

DO - 10.1016/j.ymthe.2004.02.022

M3 - Article

C2 - 15194062

AN - SCOPUS:3042775005

VL - 9

SP - 955

EP - 963

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -